Humacyte, Inc.
HUMA
NASDAQ·Healthcare·Biotechnology·Mkt cap $101.6M
$0.60
▲ +1.49%
P/E
-1.19
Mkt Cap
$101.6M
52-Wk Range
$0.53–$2.55
52-Week Range
$0.53 - $2.55
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 57.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary acellular vessel technology eliminating immune rejection and foreign body response
- Off-the-shelf, ready-to-use product format reducing surgical complexity and time
- Broad therapeutic portfolio addressing multiple high-value vascular and cellular therapy markets
- Established manufacturing platform enabling scalability across diverse anatomic locations
Bear Case
1 risk
- High volatility (beta 2.5). Larger-than-normal price swings expected.
Growth
Strong growth ahead
Expanding clinical pipeline with multiple investigational HAV programs in development
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-56.2% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying HUMA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 6, 2026
AUG 12, 2026
Reported EPS of -$0.16 vs -$0.11 consensus (-41.0% surprise). Revenue of $406.0K vs $1.0M expected (-61.0%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-41.0%
Revenue trend · last 8Q
—
—
—
—
—
-94%
-4%
+35%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$7.2M
$517.0K
$301.0K
$753.0K
$467.0K
$495.0K
$406.0K
Margins · last 8Q
Gross
0.0%
Profit
-9064.5%
Wall Street consensus
7 analysts · 86% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
86%
Hold
14%
Sell
0%
Median Price Target
—
Latest: BTIG · Aug 12, 2026
vs Industry
How HUMA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related